Company Profile

Arteriocyte Medical Systems Inc (AKA: Arteriocyte~AMS)
Profile last edited on: 5/29/21      CAGE: 483B3      UEI:

Business Identifier: Improved surgical procedures outcomes based on cell and tissue based therapies
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

7100 Euclid Avenue
Cleveland, OH 44103
   (216) 456-9640
Location: Multiple
Congr. District: 11

Public Profile

Originally launched as as spin off from Ateriocyte Inc. (stem cell therapeutics) and DW Healthcare Partnera with $10mm financing, in October 2016, it was announced that Arteriocyte Medical Systems had been acquired by ISTO Holding on behalf of ISTO Technologies. Functioning as Isto Biologics, the new firm is structured to offer evidence-based solutions to expand its orthopedics, spine and functional-medicine product portfolios. With facilities in Cleveland OH, Hopkinton, MA, Rogers, MN and Salt Lake City, Utah, Arteriocyte Medical Systems, Inc., previously had been a medical device company, developing and marketing medical products to improve surgical outcomes in cardiac, orthopedic, and vascular surgeries. The company now offers autologous platelet separator system, an automated platelet separator system that is designed for physicians, clinicians, and technicians; and sterile disposables. In 2007 - soon after the creation of the firm, AMS had acquired Medtronic's Magellan platelet system. Arteriocyte went on to develop new treatment strategies that couple its novel cellular therapies with the innovative delivery platforms. ead product is the MAGELLAN® Autologous Platelet Separator. The firm's lead product, MAGELLAN® System provides surgeons the ability to separate peripheral blood or a combination of peripheral blood and bone marrow from a patient, for that patient, at bedside in approximately 15 minutes

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Donald J Brown -- Chief Executive Officer

  Bela Anand-Apte

  Brian Barnes -- Vice President,Clinical and Regulatory Affairs

  Christopher J Coope

  Stephen E Fischer

  Danielle Holtschlag -- U.S. Vice President, Sales and Marketing

  John Mitchell -- Chief Financial Officer; Chief Operating Officer

  Vincent Pompili -- Chief Medical Officer; Clinical Director

  Ramasamy Sakthivel -- Vice President of Research and Development

  Adam Sorkin